GERMANTOWN, Md.--(BUSINESS WIRE)--Nov 5, 2020--

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the company plans to participate in the upcoming Credit Suisse virtual Healthcare Conference.

Management is scheduled to present Wednesday, November 11, 2020 at 10:15 am ET. Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com.

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics' CGM Systems, Eversense® and Eversense® XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

CONTACT: Senseonics Investor Relations Contact:

Lynn Lewis or Philip Taylor

Investor Relations

415-937-5406

KEYWORD: UNITED STATES NORTH AMERICA MARYLAND

INDUSTRY KEYWORD: MEDICAL SUPPLIES HEALTH MEDICAL DEVICES DIABETES TECHNOLOGY MOBILE/WIRELESS SOFTWARE

SOURCE: Senseonics Holdings, Inc.

Copyright Business Wire 2020.

PUB: 11/05/2020 04:05 PM/DISC: 11/05/2020 04:06 PM

Copyright Business Wire 2020.